Sources 5/8/24

VNDA
https://www.businesswire.com/news/home/20240507321726/en/Future-Pak-Increases-Bid-for-Vanda-Pharmaceuticals-to-Include-CVRs-in-Addition-to-7.25-to-7.75-Per-Share-in-Cash
https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-confirms-receipt-of-revised-unsolicited-takeover-proposal-from-future-pak-302138395.html

Patent Cliff
https://www.proclinical.com/blogs/2024-2/top-10-drugs-with-patents-due-to-expire-in-the-next-5-years
https://www.axios.com/2019/02/05/pfizer-vaccine-prevnar-top-selling-drug
https://www.reuters.com/business/healthcare-pharmaceuticals/merck-posts-better-than-expected-quarterly-results-soaring-keytruda-sales-2024-02-01/#:~:text=Keytruda%20generated%20%2425%20billion%20in,tab%20blockbuster%20arthritis%20drug%20Humira.
https://www.clinicaltrialsarena.com/analyst-comment/opdivo-checkpoint-inhibitor-fda-approval/
https://www.pharmavoice.com/news/pharma-patent-cliff-Merck-Keytruda-Pfizer-Seagen-Humira/652914/

LYRA
https://investors.lyratherapeutics.com/news-releases/news-release-details/lyra-therapeutics-reports-topline-results-phase-3-enlighten-1
